Long-term Follow-up of Glycemic and Neurological Outcomes in an International Series of Patients With Sulfonylurea-Treated ABCC8 Permanent Neonatal Diabetes

Author:

Bowman Pamela12ORCID,Mathews Frances12,Barbetti Fabrizio34ORCID,Shepherd Maggie H.12,Sanchez Janine5,Piccini Barbara6,Beltrand Jacques789ORCID,Letourneau-Freiberg Lisa R.10,Polak Michel789,Greeley Siri Atma W.10,Rawlins Eamon2,Babiker Tarig2,Thomas Nicholas J.2,De Franco Elisa2ORCID,Ellard Sian2,Flanagan Sarah E.2,Hattersley Andrew T.12ORCID,Mohsin Fauzia,Cummings Elizabeth,LeGault Laurent,Punthakee Zubin,Van Der Meulen John,Codner Ethel,Gallardo Vivian,Rafiq Meena,Houghton Jayne,Amratlal Patel Kashyap,Ford Tamsin,Kumaraguru Pillai Janani,Finn Roisin,Chakera Ali,Raile Klemens,Schebek Martin,Werner Andrea,Jain Vandana,Heffernan Emmeline,Iovane Brunella,Russo Lucia,De Galan Bastiaan,Voorhoeve Paul,Njolstad Pal,Sulen Asta,Dankovcikova Adriana,Gasperikova Daniela,Stanik Juraj,Aydin Banu,Bas Firdevs,Bundak Ruveyde,Darendeliler Feyza,Raceala-Motoc Stanca,Sanchez Juan C.,Bauer Katherine E.,Greeley Kara W.,

Affiliation:

1. Exeter NIHR Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, U.K.

2. Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, U.K.

3. Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy

4. Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy

5. Miller School of Medicine, University of Miami, Miami, FL

6. Regional Center for Pediatric Diabetes, Meyer University Children’s Hospital, Florence, Italy

7. Service d’Endocrinologie, Gynécologie et Diabétologie Pédaitrique, APHP Centre, Université de Paris, Paris, France

8. INSERM U1016, Paris, France

9. Institut IMAGINE, Paris, France

10. Kovler Diabetes Center, The University of Chicago, Chicago, IL

Abstract

OBJECTIVE ABCC8 mutations cause neonatal diabetes mellitus that can be transient (TNDM) or, less commonly, permanent (PNDM); ∼90% of individuals can be treated with oral sulfonylureas instead of insulin. Previous studies suggested that people with ABCC8-PNDM require lower sulfonylurea doses and have milder neurological features than those with KCNJ11-PNDM. However, these studies were short-term and included combinations of ABCC8-PNDM and ABCC8-TNDM. We aimed to assess the long-term glycemic and neurological outcomes in sulfonylurea-treated ABCC8-PNDM. RESEARCH DESIGN AND METHODS We studied all 24 individuals with ABCC8-PNDM diagnosed in the U.K., Italy, France, and U.S. known to transfer from insulin to sulfonylureas before May 2010. Data on glycemic control, sulfonylurea dose, adverse effects including hypoglycemia, and neurological features were analyzed using nonparametric statistical methods. RESULTS Long-term data were obtained for 21 of 24 individuals (median follow-up 10.0 [range 4.1–13.2] years). Eighteen of 21 remained on sulfonylureas without insulin at the most recent follow-up. Glycemic control improved on sulfonylureas (presulfonylurea vs. 1-year posttransfer HbA1c 7.2% vs. 5.7%, P = 0.0004) and remained excellent long-term (1-year vs. 10-year HbA1c 5.7% vs. 6.5%, P = 0.04), n = 16. Relatively high doses were used (1-year vs. 10-year dose 0.37 vs. 0.25 mg/kg/day glyburide, P = 0.50) without any severe hypoglycemia. Neurological features were reported in 13 of 21 individuals; these improved following sulfonylurea transfer in 7 of 13. The most common features were learning difficulties (52%), developmental delay (48%), and attention deficit hyperactivity disorder (38%). CONCLUSIONS Sulfonylurea treatment of ABCC8-PNDM results in excellent long-term glycemic control. Overt neurological features frequently occur and may improve with sulfonylureas, supporting early, rapid genetic testing to guide appropriate treatment and neurodevelopmental assessment.

Funder

Diabetes UK

National Institute for Health Research

Wellcome Trust

National Institute of Diabetes and Digestive and Kidney Diseases

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3